In a phase II trial of the anti-PD-1 mAb balstilimab in 140 pts with previously-treated recurrent/met cervical cancer, the ORR was 15%, including 5 CRs and 16 PRs, with a mDoR of 15.4 months. The ORR was 20% vs 7.9% in those with PD-L1+ vs PD-L1– tumours:…
42,522 followers
2,305 followers
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or m… https://t.co/I7rWx8jvFe #hvhebron #onco [Text complet]
609 followers
RT @Agenus_Bio: Results from a Ph2 trial of #antiPD1 balstilimab monotherapy in advanced #cervicalcancer published in Gynecologic Oncology…
11,292 followers
RT @Agenus_Bio: Results from a Ph2 trial of #antiPD1 balstilimab monotherapy in advanced #cervicalcancer published in Gynecologic Oncology…